Observing patients with desmoid-type fibromatosis

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to closely monitor individuals diagnosed with desmoid-type fibromatosis for a duration of one month. Participants will undergo cross-sectional imaging, such as MRI or CT scans, to assess their condition. The study includes both newly diagnosed and recurrent cases, allowing for the collection of baseline scans and biospecimens. The goal is to gather detailed information about the disease's progression and characteristics.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Clinical diagnosis of desmoid fibromatosis, either new or newly recurrent. Both patients with sporadic and FAP-associated disease will be eligible for inclusion. Patients with clinical diagnosis of desmoid (as assessed by MSK physician) but without pathologic diagnosis may be enrolled on the study to facilitate acquisition of appropriately protocoled baseline scans and allow for biospecimen collection; these patients will be replaced for purposes of analysis if pathology does not confirm clinical diagnosis.
* At least 18 years of age.
* Able to undergo cross-sectional imaging by either MRI or CT with intravenous contrast
* Disease detectable on cross-sectional imaging with target lesion measuring \>/= 1 cm
* Eligible for management by active observation as assessed by primary MSK care provider
* Willing and able to sign an informed consent document

Exclusion Criteria:

* Symptomatic desmoid fibromatosis requiring narcotic pain control, resulting in intestinal fistulization, or requiring inpatient admission during the 3 months prior to enrollment
* Patients with intraabdominal desmoids greater than 7cm in diameter or localized within 1cm of the central mesenteric vessels and those with tumors in the head and neck
* KPS performance status \</= 70 if performance status is limited due to tumor. Patients with low KPS performance status related to co-morbidities but without symptoms related to the tumor will be eligible for enrollment.
* Age less than 18 years old
* Strict contraindication for both cross-sectional MRI and CT imaging with intravenous contrast (e.g., as per standard institutional protocols regarding renal insufficiency or MRI incompatible implanted devices; patients requiring pre-medication to prevent contrast reactions will be eligible for study)
* Unable to grant reliable informed consent
* Ongoing systemic treatment for desmoid fibromatosis

Where it's running

• Memorial Sloan Kettering Cancer Center
  New York, New York, United States Recruiting

Study contacts

• Principal investigator: Aimee M Crago, MD, PhD — Memorial Sloan Kettering Cancer Center
• Study coordinator: Aimee M Crago, MD, PhD
• Email: cragoa@mskcc.org
• Phone: 212-639-4807

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Arterial embolization for desmoid fibromatosis

  This trial tries blocking the tumor blood supply with embolic material (no chemotherapy) in people aged 12 and up who have symptomatic, actively growing desmoid fibromatosis and are not candidates for surgery or cryoablation.

  Recruiting Istituto Ortopedico Rizzoli · Bologna, BO · NCT06945887

• Gathering health information for younger cancer patients

  This study is gathering health information from younger cancer patients to help improve treatments and support future research.

  Recruiting at 253 sites Children's Oncology Group · Birmingham, Alabama and 278 other locations · NCT02402244

• Retifanlimab after chemoradiation for anal cancer

  This study tests whether retifanlimab can help people with anal squamous cell carcinoma who have completed chemoradiation and still have residual disease.

  Recruiting at 7 sites Phase 2 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT07927998

• Different skin care approaches to prevent skin reactions after mastectomy radiation

  This study tests three standard skin care methods to see which best prevents radiation dermatitis in people who had a mastectomy and are receiving post-mastectomy radiation therapy.

  Recruiting at 7 sites Phase 2 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT07918989

• Graft-versus-host disease after stem cell transplant: testing LBP-MARCO with ruxolitinib

  We are testing whether combining LBP-MARCO with ruxolitinib is safe for adults with GVHD after a stem cell transplant.

  Recruiting at 7 sites Phase 1 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT07913672

• 68Ga-FAPI PET/MRI imaging to see if it can track breast cancer response to chemotherapy

  This study tests whether a new imaging scan, 68Ga-FAPI PET/MRI, can show how well invasive breast cancer responds to neoadjuvant chemotherapy in adults.

  Recruiting at 8 sites Phase 1 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 7 other locations · NCT07899892

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.